| Scientific Name | Tofacitinib |
|---|---|
| Brand Name | Xeljanz |
| Risk | Risk of Major Adverse Cardiovascular Events and Malignancies (Excluding NMSC) with Use of Xeljanz/Xeljanz XR (tofacitinib) Relative to TNFi Therapy. Safety information about monitoring and Increased risk of pulmonary embolism and overall mortality with higher dose of XELJANZ (tofacitinib) for rheumatoid arthritis. |
